WO1995007992A3 - Cloned glutamic acid decarboxylase - Google Patents

Cloned glutamic acid decarboxylase Download PDF

Info

Publication number
WO1995007992A3
WO1995007992A3 PCT/US1994/009478 US9409478W WO9507992A3 WO 1995007992 A3 WO1995007992 A3 WO 1995007992A3 US 9409478 W US9409478 W US 9409478W WO 9507992 A3 WO9507992 A3 WO 9507992A3
Authority
WO
WIPO (PCT)
Prior art keywords
glutamic acid
acid decarboxylase
cloned
cloned glutamic
gad
Prior art date
Application number
PCT/US1994/009478
Other languages
French (fr)
Other versions
WO1995007992A2 (en
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Michael J Clare-Salzler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Priority to DE69431060T priority Critical patent/DE69431060T2/en
Priority to DK94927940T priority patent/DK0719340T3/en
Priority to AT94927940T priority patent/ATE221125T1/en
Priority to CA2170523A priority patent/CA2170523C/en
Priority to AU79201/94A priority patent/AU697058B2/en
Priority to EP94927940A priority patent/EP0719340B1/en
Priority to JP07509191A priority patent/JP3133339B2/en
Publication of WO1995007992A2 publication Critical patent/WO1995007992A2/en
Publication of WO1995007992A3 publication Critical patent/WO1995007992A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)

Abstract

Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
PCT/US1994/009478 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase WO1995007992A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69431060T DE69431060T2 (en) 1993-09-17 1994-08-24 CLONED GLUTAMIC ACID DECARBOXYLASE
DK94927940T DK0719340T3 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase
AT94927940T ATE221125T1 (en) 1993-09-17 1994-08-24 CLONED GLUTAMINE ACID DECARBOXYLASE
CA2170523A CA2170523C (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase
AU79201/94A AU697058B2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase
EP94927940A EP0719340B1 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase
JP07509191A JP3133339B2 (en) 1993-09-17 1994-08-24 Cloned glutamate decarboxylase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/123,859 1993-09-17
US08/123,859 US5674978A (en) 1990-09-21 1993-09-17 Peptides derived from glutamic acid decarboxylase

Publications (2)

Publication Number Publication Date
WO1995007992A2 WO1995007992A2 (en) 1995-03-23
WO1995007992A3 true WO1995007992A3 (en) 1995-06-22

Family

ID=22411325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009478 WO1995007992A2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase

Country Status (11)

Country Link
US (5) US5674978A (en)
EP (1) EP0719340B1 (en)
JP (1) JP3133339B2 (en)
KR (1) KR100367943B1 (en)
AT (1) ATE221125T1 (en)
AU (1) AU697058B2 (en)
CA (1) CA2170523C (en)
DE (1) DE69431060T2 (en)
DK (1) DK0719340T3 (en)
ES (1) ES2179077T3 (en)
WO (1) WO1995007992A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004632A1 (en) 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
JPH06508030A (en) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド Cloning and expression of human pancreatic islet glutamate decarboxylase autoantigen
US5691448A (en) * 1992-12-03 1997-11-25 Baekkeskov; Steinunn Reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
CN1112933A (en) * 1994-01-20 1995-12-06 伯伦格·曼海姆有限公司 Antigen-specific, activated T lymphocytes, detection and use
EP1849870A1 (en) * 1995-02-20 2007-10-31 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
DE19525784A1 (en) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreactive peptides from human glutamine decarboxylase (GAD)
DE19526561A1 (en) * 1995-07-20 1997-01-23 Boehringer Mannheim Gmbh In vivo diabetes test
AU2044197A (en) * 1996-04-01 1997-10-22 Chugai Seiyaku Kabushiki Kaisha Diagnostic composition for diseases accompanied by autoimmune reactions caused by 65k-glutamic acid decarboxylase
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
FR2759701B1 (en) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med USE OF ULIP PROTEINS IN THE DIAGNOSIS AND THERAPY OF CANCER AND PARANEOPLASTIC NEUROLOGICAL SYNDROMES
EP1030679A4 (en) * 1997-10-17 2003-03-05 Univ Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
SE9704451D0 (en) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
WO1999037315A1 (en) * 1998-01-27 1999-07-29 Bai Jane Pei Fan Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2001013934A1 (en) * 1999-08-23 2001-03-01 Virginia Mason Research Center Peptide and peptide analogues for the treatment and prevention of diabetes
US6713058B2 (en) * 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
ATE398678T1 (en) * 2000-04-10 2008-07-15 Merk Und Kollegen Gmbh Lab Dr FUSION PROTEIN FOR THE SIMULTANEOUS DETECTION OF HUMAN AUTOANTIBODIES
EP1275003A2 (en) 2000-04-19 2003-01-15 Research Corporation Technologies, Inc Diagnostic assay for endometriosis
US7178152B2 (en) * 2001-03-01 2007-02-13 Sony Corporation Application programming interface for communication between audio/video file system and audio video controller
JP4594588B2 (en) * 2001-04-10 2010-12-08 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Therapeutic and diagnostic uses of antibody-specific profiles
US20050130245A1 (en) * 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
WO2004035084A2 (en) * 2002-10-02 2004-04-29 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EP1755631A2 (en) * 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US7994279B2 (en) * 2006-04-04 2011-08-09 The University Of Toledo Altered peptide ligands of GAD65
CN100450552C (en) * 2006-05-26 2009-01-14 中国医学科学院医学生物学研究所 Vaccine for diabetes in type I, and constructing method
US20090098631A1 (en) * 2006-08-01 2009-04-16 Neurologix, Inc. Novel glutamic acid decarboxylase (GAD) proteins and methods of use
US20100279422A1 (en) * 2006-08-21 2010-11-04 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis
WO2008036465A2 (en) * 2006-09-18 2008-03-27 CMED Technologies Ltd. Office of Walkers Limited A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
WO2008036470A2 (en) * 2006-09-19 2008-03-27 Cmed Technologies Ltd. A method for screening of infectious agents in blood
US20100047815A1 (en) * 2006-09-21 2010-02-25 Cmed Technologies Ltd. Method to detect tumor markers and diagnosis of undifferentiated tumors
WO2008070223A2 (en) * 2006-09-21 2008-06-12 Cmed Technologies Ltd. A method to remove repetitive sequences from human dna
WO2008066982A2 (en) * 2006-09-25 2008-06-05 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic aberrations in patients with chronic lymphocytic leukemia
WO2008082710A2 (en) * 2006-09-25 2008-07-10 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic aberrations in patients with multiple myeloma
WO2008085554A2 (en) * 2006-09-25 2008-07-17 Cmed Technologies Ltd. A method to detect virus related immunologigal markers for the diagnosis of hepatitis b virus infection
WO2008070227A2 (en) * 2006-09-25 2008-06-12 Cmed Technologies Ltd. A method for the identification of human immunodeficiency virus related antibodies in blood
WO2008057652A2 (en) * 2006-09-25 2008-05-15 Cmed Technologies Ltd. A method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection
US20100047789A1 (en) * 2006-09-25 2010-02-25 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic disorders for postnatal diagnosis
WO2008066996A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method to detect treponema pallidum immunological markers for the diagnosis of syphilis
US8114682B2 (en) * 2006-09-27 2012-02-14 Cmed Technologies Ltd. Method for the quantitative evaluation of sex hormones in a serum sample
US20100004872A1 (en) * 2006-09-27 2010-01-07 Cmed Technologies Ltd. Method for quantitative measurement of cardiac biochemical markers
US8158343B2 (en) * 2006-09-27 2012-04-17 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of respiratory tract infections
US20100021930A1 (en) * 2006-09-27 2010-01-28 Cmed Technologies Ltd. Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects
US8110409B2 (en) * 2006-09-27 2012-02-07 Cmed Technologies Ltd. Method to measure serum biomarkers for the diagnosis of liver fibrosis
WO2008067006A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative detection of diabetes related immunological markers
WO2008067007A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
JP5378202B2 (en) * 2007-03-15 2013-12-25 株式会社リバース・プロテオミクス研究所 Biomarkers specific to the brain and nerves or specific to neural differentiation
LT2821494T (en) 2007-03-16 2017-04-25 Genomatica, Inc. Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
JP2010525049A (en) * 2007-04-24 2010-07-22 ダイアミド セラピューティクス アーベー Drugs and methods for treating autoimmune diseases and cancer
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
EP2193206A4 (en) 2007-10-04 2011-02-02 Cmed Technologies Ltd Application of surface plasmon resonance technology for detecting and genotyping hpv
EP3514242A3 (en) 2008-09-10 2019-08-28 Genomatica, Inc. Microrganisms for the production of 1,4-butanediol
DK2367561T3 (en) 2008-11-30 2015-08-24 Immusant Inc Configurations and methods for treatment of celiac
JP6133599B2 (en) 2009-06-04 2017-05-24 ゲノマチカ， インク． Method for separating components of fermentation broth
CN113528417A (en) 2009-06-04 2021-10-22 基因组股份公司 Microorganisms for producing 1, 4-butanediol and related methods
JP2013507145A (en) * 2009-10-13 2013-03-04 ゲノマチカ， インク． Microorganisms and related methods for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA, putrescine and related compounds
US8530210B2 (en) 2009-11-25 2013-09-10 Genomatica, Inc. Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone
US8637286B2 (en) 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
CN104380112B (en) 2012-04-13 2017-05-24 迪亚贝托米克斯有限公司 Maternal biomarkers for gestational diabetes
CN111705028A (en) 2012-06-04 2020-09-25 基因组股份公司 Microorganisms and methods for making 4-hydroxybutyrate, 1, 4-butanediol, and related compounds
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
AU2015268960B2 (en) * 2014-06-04 2020-04-09 Diamyd Medical Ab Novel combinations for antigen based therapy
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
US10473647B1 (en) 2014-11-21 2019-11-12 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
TWI655812B (en) 2016-07-20 2019-04-01 松下知識產權經營股份有限公司 Suspended socket
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020811A2 (en) * 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
EP0519469A1 (en) * 1991-06-18 1992-12-23 The Regents Of The University Of California Cloned glutamic acid decarboxylase

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
KR910700459A (en) * 1988-12-13 1991-03-15 수잔 우레이 Methods and compositions for early screening and treatment of insulin dependent diabetes mellitus
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
NO306996B1 (en) * 1989-02-17 2000-01-24 Bayer Ag Isolated pancreatic cell (ICA) antigen for in vitro use
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
ATE144326T1 (en) * 1990-08-17 1996-11-15 Univ Florida METHOD AND COMPOSITION FOR EARLY DETECTION AND TREATMENT OF INSULIN-DEPENDENT DIABETES
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
WO1992006105A1 (en) * 1990-10-02 1992-04-16 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
WO1992014485A1 (en) * 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
EP0703783B1 (en) * 1993-03-05 2010-05-05 Epimmune Inc. Methods of making immunogenic hla-a2.1 binding peptides
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020811A2 (en) * 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
EP0519469A1 (en) * 1991-06-18 1992-12-23 The Regents Of The University Of California Cloned glutamic acid decarboxylase

Also Published As

Publication number Publication date
CA2170523C (en) 2010-03-30
CA2170523A1 (en) 1995-03-23
ATE221125T1 (en) 2002-08-15
KR960705051A (en) 1996-10-09
DE69431060D1 (en) 2002-08-29
EP0719340B1 (en) 2002-07-24
JPH09503387A (en) 1997-04-08
WO1995007992A2 (en) 1995-03-23
US6011139A (en) 2000-01-04
AU7920194A (en) 1995-04-03
EP0719340A1 (en) 1996-07-03
US8926966B1 (en) 2015-01-06
DE69431060T2 (en) 2002-11-14
US5846740A (en) 1998-12-08
DK0719340T3 (en) 2002-11-18
KR100367943B1 (en) 2003-06-18
ES2179077T3 (en) 2003-01-16
AU697058B2 (en) 1998-09-24
JP3133339B2 (en) 2001-02-05
US5674978A (en) 1997-10-07
US6455267B1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
WO1995007992A3 (en) Cloned glutamic acid decarboxylase
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
CA2219988A1 (en) Cd16-ii variants
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
AU625963B3 (en) L-phenylalanyl-tRNA synthetase mutants, a process for the preparation thereof and the use thereof for the in vivo incorporation of non-proteinogenous amino acids into peptides or proteins
WO1996019580A3 (en) Telomerase protein component
IE842881L (en) Atrial peptides
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
HUP9800049A3 (en) Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
GB2367061A (en) Peptides
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
IE882628L (en) Substituted 2-phenyl-4-quinoline carboxylic acids
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU1384995A (en) Human circulating cytokine cc-1
IE873239L (en) Variants of hirudin
WO1995030001A3 (en) Novel p-selectin ligand protein
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
CA2070004A1 (en) Cloned glutamic acid decarboxylase
EP1443055A3 (en) Interleukins-21 and 22
AU1086888A (en) Primary biliary cirrhosis autoantigen
EP1431391A3 (en) Rantes mutants and therapeutic applications thereof
EP0317279A3 (en) Peptides for use in the purification of factor viii
CA2259640A1 (en) Human glycine transporter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994927940

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2170523

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994927940

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994927940

Country of ref document: EP